Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2017 | Pages:
67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape. Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 4, 6, 3, 3 and 1 respectively. Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Onychomycosis (Tinea Unguium) - Overview Onychomycosis (Tinea Unguium) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Onychomycosis (Tinea Unguium) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development Almirall SA Arno Therapeutics Inc Blueberry Therapeutics Ltd Dermala Inc Eisai Co Ltd Helix BioMedix Inc Hexima Ltd Meiji Seika Pharma Co Ltd Moberg Pharma AB NAL Pharmaceuticals Ltd Nihon Nohyaku Co Ltd Novabiotics Ltd Novan Inc Viamet Pharmaceuticals Inc Onychomycosis (Tinea Unguium) - Drug Profiles AR-12 - Drug Profile Product Description Mechanism Of Action R&D Progress BB-0305 - Drug Profile Product Description Mechanism Of Action R&D Progress BB-2603 - Drug Profile Product Description Mechanism Of Action R&D Progress Drug for Onychomycosis - Drug Profile Product Description Mechanism Of Action R&D Progress ELS-160 - Drug Profile Product Description Mechanism Of Action R&D Progress fosravuconazole - Drug Profile Product Description Mechanism Of Action R&D Progress HB-1275 - Drug Profile Product Description Mechanism Of Action R&D Progress HXP-124 - Drug Profile Product Description Mechanism Of Action R&D Progress luliconazole - Drug Profile Product Description Mechanism Of Action R&D Progress ME-1111 - Drug Profile Product Description Mechanism Of Action R&D Progress NAL-3210 - Drug Profile Product Description Mechanism Of Action R&D Progress NP-213 - Drug Profile Product Description Mechanism Of Action R&D Progress P-3058 - Drug Profile Product Description Mechanism Of Action R&D Progress SB-208 - Drug Profile Product Description Mechanism Of Action R&D Progress terbinafine hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress terbinafine hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress VT-1161 - Drug Profile Product Description Mechanism Of Action R&D Progress Onychomycosis (Tinea Unguium) - Dormant Projects Onychomycosis (Tinea Unguium) - Discontinued Products Onychomycosis (Tinea Unguium) - Product Development Milestones Featured News & Press Releases Sep 28, 2016: Moberg Pharma Begins Patient Enrollment in North America and Europe in Two Phase 3 Studies of MOB-015 in Onychomycosis Aug 10, 2016: Moberg Pharma Announces Approvals to Start Phase 3 Study For MOB-015 In U.S. And Canada Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program Jul 13, 2016: Viamet to Present Interim RENOVATE Results at the American Podiatric Medical Association 2016 Annual Meeting Jul 05, 2016: Moberg Pharma announces submission of applications to start Phase 3 studies for MOB-015 May 18, 2016: Moberg Pharma Announces Multiple Patent Approvals for MOB-015 Mar 02, 2016: Viamet Reports Positive Results from Interim Analysis of RENOVATE Phase 2b Trial of VT-1161 in Onychomycosis Jan 21, 2016: Moberg Pharma is contemplating a potential bond issue, updates financial targets and provides update on MOB-015 Jan 07, 2016: Viamet to Present at the 3rd Annual Dermatology Summit Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus) Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Arno Therapeutics Inc, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Dermala Inc, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co Ltd, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix Inc, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co Ltd, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Novan Inc, H1 2017 Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals Inc, H1 2017 Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2017 Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2017 (Contd..1), H1 2017 Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
